Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

IGCS 2012

13 - 16 Oct 2012
Geneva Palexpo, Geneva, Switzerland
Effectiveness of PARP inhibitors in ovarian cancer
Prof Jonathan Ledermann - University College London, UK
Effectiveness of PARP inhibitors in ovarian cancer ( Prof Jonathan Ledermann - University College London, UK )
1 Nov 2012
Issues in sentinel node mapping in endometrial and vulva cancer
Prof Henry Kitchener – Manchester University, UK
Issues in sentinel node mapping in endometrial and vulva cancer ( Prof Henry Kitchener – Manchester University, UK )
31 Oct 2012
Complications in surgical approaches due to obesity
Dr Paola Gehrig – University of North Carolina, Chapel Hill, USA
 Complications in surgical approaches due to obesity ( Dr Paola Gehrig – University of North Carolina, Chapel Hill, USA )
31 Oct 2012
Radical hysterectomy of cervical cancer
Dr Shingo Fujii – Kitano Hospital, Osaka, Japan
Radical hysterectomy of cervical cancer ( Dr Shingo Fujii – Kitano Hospital, Osaka, Japan )
31 Oct 2012
Retrospective study on adjuvant therapy in vulva cancer
Prof Sven Mahner - University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Retrospective study on adjuvant therapy in vulva cancer ( Prof Sven Mahner - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
31 Oct 2012
Phase III HECTOR study: recurring platinum sensitive ovarian cancer
Prof Sven Mahner - University Medical Center Hamburg-Eppendorf , Hamburg, German...
Phase III HECTOR study: recurring platinum sensitive ovarian cancer ( Prof Sven Mahner - University Medical Center Hamburg-Eppendorf , Hamburg, Germany )
31 Oct 2012
GOG 209 study: optimal management of advanced endometrial cancer
Prof David Miller – University of Texas Southwestern Medical Centre, Dallas, USA
GOG 209 study: optimal management of advanced endometrial cancer ( Prof David Miller – University of Texas Southwestern Medical Centre, Dallas, USA )
31 Oct 2012
AURELIA trial, palliative chemotherapy with bevacizumab in resistant, recurrent ...
Dr Gunnar Kristensen – Norwegian Radium Hospital, Oslo, Norway
AURELIA trial, palliative chemotherapy with bevacizumab in resistant, recurrent ovarian cancer ( Dr Gunnar Kristensen – Norwegian Radium Hospital, Oslo, Norway )
30 Oct 2012
The Cancer Genome Atlas and high grade serous ovarian cancer
Dr Andrew Berchuck – Duke University Medical Center, Durham, USA
The Cancer Genome Atlas and high grade serous ovarian cancer ( Dr Andrew Berchuck – Duke University Medical Center, Durham, USA )
30 Oct 2012
Benefits of nomogram versus staging in cervical cancer
Dr Stephen Polterauer – Medical University of Vienna, Austria
Benefits of nomogram versus staging in cervical cancer ( Dr Stephen Polterauer – Medical University of Vienna, Austria )
30 Oct 2012
Gestational trophoblastic disease tumours in high risk patients
Dr Michael Seckl – Charing Cross Hospital, Imperial College London, UK
Gestational trophoblastic disease tumours in high risk patients ( Dr Michael Seckl – Charing Cross Hospital, Imperial College London, UK )
30 Oct 2012
Late effects of treatment in gynaecological cancers
Dr Remi Nout – Leiden University Medical Center, Netherlands
Late effects of treatment in gynaecological cancers ( Dr Remi Nout – Leiden University Medical Center, Netherlands )
30 Oct 2012
Staging in endometrial cancer and sentinel node mapping
Dr Charles Levenback – MD Anderson Cancer Center, Houston, TX, USA
Staging in endometrial cancer and sentinel node mapping ( Dr Charles Levenback – MD Anderson Cancer Center, Houston, TX, USA )
30 Oct 2012
OCTAVIA trial: bevacizumab and paclitaxel treatment for ovarian cancer
Dr Antonio Gonzalez-Martin – MD Anderson Cancer Center, Madrid, Spain
OCTAVIA trial: bevacizumab and paclitaxel treatment for ovarian cancer ( Dr Antonio Gonzalez-Martin – MD Anderson Cancer Center, Madrid, Spain )
30 Oct 2012
State of PARP inhibitors and anti-angiogenics
Prof Stan Kaye – Royal Marsden Hospital, London, UK
State of PARP inhibitors and anti-angiogenics ( Prof Stan Kaye – Royal Marsden Hospital, London, UK )
29 Oct 2012
Study of ovarian cancer and endometriosis sub-fertility
Prof Curt Burger – Erasmus University, Rotterdam, Netherlands
Study of ovarian cancer and endometriosis sub-fertility ( Prof Curt Burger – Erasmus University, Rotterdam, Netherlands )
29 Oct 2012
New therapies to treat advanced endometrial cancer
Prof Gini Fleming – University of Chicago Medical Center, Illinois, USA
New therapies to treat advanced endometrial cancer ( Prof Gini Fleming – University of Chicago Medical Center, Illinois, USA )
29 Oct 2012
Defining and advancing individualised medicine
Prof Anil Sood – MD Anderson Cancer Centre, Houston, USA
Defining and advancing individualised medicine ( Prof Anil Sood – MD Anderson Cancer Centre, Houston, USA )
29 Oct 2012
Effects of early ovarian cancer screening
Dr Ed Pavlik – University of Kentucky, Lexington, USA
Effects of early ovarian cancer screening ( Dr Ed Pavlik – University of Kentucky, Lexington, USA )
29 Oct 2012
Sexual health during and after ovarian cancer treatment
Dr Susan Carr – Royal Women’s Hospital, Parkville, Australia
Sexual health during and after ovarian cancer treatment  ( Dr Susan Carr – Royal Women’s Hospital, Parkville, Australia )
29 Oct 2012